Italia markets closed

PFE Nov 2024 28.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,0200-0,2200 (-9,82%)
In data: 03:43PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente2,2400
Aperto1,9300
Denaro1,9500
Domanda2,0900
Prezzo d'esercizio28,00
Scadenza2024-11-15
Min-Max giorno1,9000 - 2,0700
Contratto - Min-MaxN/D
Volume384
Open Interest7,48k
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g